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Predictors of CD4 count over time 
among HIV patients initiated ART in Felege 




Background: The response of HIV patients to antiretroviral therapy could be measured by its strong predictor, the 
CD4+ T cell (CD4) count for the initiation of antiretroviral therapy and proper management of disease progress. 
However, in addition to HIV, there are other factors which can influence the CD4 cell count. Patient’s socio-economic, 
demographic, and behavioral variables, accessibility, duration of treatment etc., can be used to predict CD4 count.
Methods: A retrospective cohort study was conducted to examine the predictors of CD4 count among ART users 
enrolled in the first 6 months of 2010 and followed upto mid 2014. The covariance components model was employed 
to determine the predictors of CD4 count over time.
Results: A total of 1196 ART attendants were used to analyze their data descriptively. Eight hundred sixty-one of the 
attendants had two or more CD4 count measurements and were used in modeling their data using the linear mixed 
method. Thus, the mean rates of incensement of CD4 counts for patients with ambulatory/bedridden and working 
baseline functional status were 17.4 and 30.6 cells/mm3 per year, respectively. After adjusting for other variables, for 
each additional baseline CD4 count, the gain in CD4 count during treatment was 0.818 cells/mm3 (p value <0.001). 
Patient’s age and baseline functional status were also statistically significantly associated with CD4 count.
Conclusion: In this study, higher baseline CD4 count, younger age, working functional status, and time in treatment 
contributed positively to the increment of the CD4 count. However, the observed increment at 4 year was unsatisfac-
tory as the proportion of ART users who reached the normal range of CD4 count was very low. To see their long term 
treatment outcome, it requires further research with a sufficiently longer follow up data. In line with this, the local CD4 
count for HIV negative persons should also be investigated for better comparison and proper disease management.
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Background
HIV/AIDS is one of the major public health problems in 
Sub-Saharan Africa, and Ethiopia, as one of these coun-
tries has been affected by the epidemic with a prevalence 
of 1.5  % [1]. Its burden has been high in the Amhara 
Region, including the catchment area of Felege Hiwot 
Referral Hospital where this study was conducted.
Currently, the only available treatment for HIV/AIDS 
is antiretroviral therapy (ART). Because HIV affects the 
CD4+ T-cell (CD4) counts in the human body, it can be 
employed to make appropriate decisions for the initia-
tion of ART and proper management of the progression 
of the infection [2, 3]. For instance, it is recommended 
that after 3  months of treatment with ART, a patient 
should gain 50–100 CD4 cells/mm3 per year, and that an 
increment below this range could imply poor response 
Open Access
BMC Research Notes
*Correspondence:  lemmagezie@gmail.com 
Department of Epidemiology and Biostatistics, Institute of Public Health, 
College of Medicine and Health Sciences, University of Gondar, Gondar, 
Ethiopia
Page 2 of 9Gezie  BMC Res Notes  (2016) 9:377 
to the treatment [4]. Patients’ CD4 count is also required 
to reach at least the lower limit of the CD4 count for the 
general healthy adult population (500  cells/mm3) [4] 
which otherwise can be an indication of immunologic 
failure.
However, in addition to HIV there are other factors 
which can affect CD4 cell counts. Among demographic 
variables, older ages are predictors of lower CD4 count 
response to ART [5, 6]. With regard to sex, females expe-
rienced better CD4 count response to ART compared to 
males as reported by a study done in North Ethiopia [7], 
but not according to other studies [5, 8].
Residence also has an effect on CD4 count at enrol-
ment [9], and measures of accessibility, like distance 
of health facility from residence can have an effect on 
timing of diagnosis [10, 11] which in turn can affect the 
CD4 count at the initiation of ART [12]. Yet, patients 
with a deteriorated CD4 count at the initiation of ART 
due to late presentation would have poor response to 
ART [13].
While WHO clinical stage is reported to be an inde-
pendent predictor of CD4 count at enrolment [9], it is 
not significantly associated with treatment response, 
according to a study that examined patients on ART for 
12 months [7]. Similarly, studies reported that there is a 
positive association between baseline CD4 count and its 
size during treatment [14]; however, other studies also 
reported negative associations [6].
Available literature indicated that no study assessed the 
level of response to ART in the current and other similar 
study settings. On top of that, there were discrepancies 
in findings for some variables, like sex. Therefore, it is 
imperative that such a study which assesses the associa-
tion between CD4 cell count against socio-demographic, 
time in treatment, accessibility, and clinical factors using 
the linear mixed method that enables to estimate the 
effect of variables considered by controlling for unmeas-
ured variables.
Identifying factors which influence the level of CD4 
count other than ART would help health profession-
als and patients to facilitate proper management and 
monitoring of health care interventions on HIV posi-
tive persons. Moreover, it helps to check whether HIV 
patients who initiated ART based on criteria formerly set 
(≤200  cells/mm3) were recovering to the normal range 
of CD4 count for the general healthy adult population 
which is 500  cells/mm3 or more [4] and is also equiva-
lent to the cutoff point set recently to initiate ART for the 
adult HIV patients in the country [15]. Thus the current 
study was conducted with the objective of determining 
the level of CD4 count and factors associated with it after 




A retrospective cohort study was conducted to assess the 
predictors of CD4 count among adult ART users enrolled 
in the first 6 months of 2010 and followed up to mid 2014.
Study area and population
The study was conducted at Felege Hiwot Referral Hos-
pital located in the capital of the Amhara Regional State, 
Ethiopia. The hospital gives Voluntary Counseling and 
Testing services in a clinic to both physician and self-
referred patients. The study population included HIV 
positive adults who initiated ART treatment in the refer-
ral hospital.
Sample size and sampling procedure
All HIV positive adults who initiated ART in the hospi-
tal from January to June, 2010 (6 months) were included 
in the sample. Therefore, 1196 patients were selected for 
the sample, and 861 of them who had two or more CD4 
count measurements were used in the multilevel analysis.
Data collection procedures
The study exclusively used secondary data. Therefore, a 
data extraction check-list was designed and used to adopt 
the routinely collected data. A baseline CD4 count data 
were identified and collected from the registration docu-
ments of ART attendants which were collected from each 
patient at the initiation of ART. Subsequent CD4 count 
data were also taken from the same sources that were col-
lected from each patient almost every 6 month. Similarly, 
other characteristics, like socio-demographic, time in 
treatment, accessibility, and clinical data were also col-
lected from the registration documents of patients.
Data structure, compilation and analysis strategy
Data were entered, cleaned, and analyzed using the sta-
tistical software called SPSS version 20. Some descriptive 
statistics were presented from all 1196 ART attendants 
using tables and graphs. However, only 861 patients who 
had two or more CD4 count measurements, including 
the baseline CD4 count data, were considered in the mul-
tilevel mixed model. That was because the CD4 count 
measurement just before the initiation of ART was con-
sidered as a covariate so that there should be at least one 
CD4 count reading that would be taken as a response 
variable after the initiation of ART.
The data structure had three levels of random group-
ing variables: the repeated measurements of CD4 count 
data (level-1), individual patients (level-2), and patients 
residence (level-3). With the identity link function, the 
multilevel linear mixed model (LMM) was employed to 
assess the effect of socio-demographic, time in treatment, 
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accessibility, and other clinical variables on the repeated 
measure of CD4 count. By taking advantages of LMM’s 
flexibility and efficiency, both the random and fixed 
effects of predictors on CD4 counts were determined.
In this study, LMM was preferred to generalized esti-
mation equation (GEE) to fit the data because the interest 
was mainly on the subject-specific (individual) interpre-
tation of effects, not on the marginal (population) aver-
age effects. There was also interest of identifying variance 
sources and their components. Following this, the maxi-
mum likelihood (ML) parameter estimation method was 
employed. The overall effect of each explanatory variable 
on the CD4 count was tested by F-test, while the effect of 
each category of each factor was tested by t-test with the 
respective degrees of freedom.
To determine the model that best fits the data, explora-
tory data analysis was done first, especially by assessing 
individual CD4 count over time using individual trajecto-
ries. In addition to the descriptive individual trajectories, 
the unconditional null model was determined to further 
strengthen the relevance of the mixed model using the 
Intra-class correlation coefficient (ICC) calculated from 
it [16]. The null model would also serve as a baseline 
model for the purposes of comparison with later, more 
complex models. Then a model containing time as its 
fixed and random effect was determined before the final 
model containing the fixed effects of variables of interest, 
the random intercept, and the random slopes was fitted.
The model selection strategy used was comparing the 
Bayesian information criteria (BIC) of models consid-
ered. Accordingly, a model with a smaller value of BIC 
was selected as far as the change in BIC was statistically 
significant at Chi square with the change in the degree of 
freedom. The type of covariance structure and the mag-
nitude of residual errors were also considered in model 
selection. In this regard, a model with the least within-
individual variation when compared to other models 
residual variability was selected. In the present study, a 
significance level of 0.05 was taken as a cut point for all 
statistical tests.
Results
Patient characteristics and description of CD4 cell counts
A total of 1196 HIV positive adults who were attending 
ART at Felege Hiwot Referral Hospital were included 
in the study. The average age of study participants was 
30.96 + 11.81 SD (standard deviation) and 666 (55.7 %) 
of them were females. The majority (721 or 60.3 %) of the 
patients were from Bahir Dar city where the hospital is 
located, while the remaining patients came from 36 other 
districts, the farthest being 265 km from the ART service 
center. These patients gave 6341 measurements of CD4 
counts during the 4 years of retrospective follow up. The 
minimum and maximum numbers of CD4 count meas-
urements per patient were 1 and 8, respectively, and the 
average number of measurements was 5.3.
Most of the participants (919 or 76.8  %) had baseline 
CD4 counts of less than 200  cells/mm3 which was the 
cutoff point to start ART for adults before the recent 
revision was made. Similarly, most participants had base-
line WHO clinical stage of III or IV (955 or 79.9 %) and 
“working” functional status as of last observation (651 or 
62.2  %). The average CD4 count increased from 150.27 
(at baseline) to 453.13 (at 4  years); and in reference to 
baseline CD4 count, most (60.26  %) of the increment 
occurred during the first 6 months of follow up, while it 
was only 66.87 % at year four or an average increment of 
6.61 % during the last three and half years (Table 1).
Out of the 1196 participants who started ART, only 378 
(31.6 %) had CD4 count measurements until the end of 
the follow up period, but only 142 (37.6 %) of these (378) 
had a CD4 count of at least 500 cells/mm3.
The difference between the average CD4 count of males 
and females increased gradually over time, males gaining 
a lesser average CD4 count. Both sexes had the highest 
average rates of increment (slope) of CD4 count during 
the first 6 months, and there after the rates of increment 
declined (Fig. 1).
Exploratory data analysis
Because the rate of increment in CD4 cell counts dur-
ing the first 6 months was so high and completely differ-
ent from the increment rate experienced after 6 months 
(Fig. 1), the model was fitted for repeated CD4 count data 
measured starting from the 6th month. Moreover, the 
CD4 count data before the initiation of ART (baseline 
CD4 count) was taken as a covariate.
For a more exploratory purpose, individual trajectories 
were graphed for the first 30 patients CD4 count (Fig. 2). 
As one could easily understand from the graph, the inter-
cepts of individual trajectories had a range of almost 
200 cells/mm3 which was a considerably large difference. 
Similarly, some trajectories were steeper while others 
were almost horizontal, indicating the possible variabil-
ity in the slope of CD4 counts. Therefore, because of the 
variability in the intercept and slope of trajectories, using 
a mixed model could fit the data very well.
Modeling the CD4 cell count data
The Intra-class Correlation Coefficient (ICC) which is the 
variability among intercepts relative to total variability is 
calculated to be 67.8 % for the null model. This value is 
greater than the minimum recommended value (25  %) 
to use a mixed model [17]. The high value of ICC had 
also further strengthened the appropriateness of using 
a mixed model for the data. Therefore, the modeling 
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process was started with the null (the unconditional 
mean) model (Table 2).
Next to the null model, the unconditional linear model 
containing a random intercept and time as both fixed 
and random effect variable was fitted. In this second 
model, the fixed intercept and slope were 350.53 and 
11.78, respectively, and both were statistically significant 
(each with a p value of less than 0.001). The random error 
terms of the intercept and slope were also statistically sig-
nificant (each with a p value of less than 0.001).
The third model included fixed predictors from differ-
ent levels to explain the variability among CD4 counts. 
As a result, three levels, including repeated CD4 count 
values, individual subjects, and residence were identi-
fied as first, second, and third levels of the data structure, 
respectively. Therefore, time since the initiation of ART 
(from level-1), baseline age, baseline CD4 count, baseline 
Table 1 Characteristics of  ART attendants, Felege Hiwot 
Referral Hospital, 2010–2014
a The mean estimates were made under the condition of changing 
denominators because of attritions
Characteristics Number (percent)
Baseline age in year (n = 1196)
 15–20 149 (12.5)
 21–30 473 (39.5)
 31–40 388 (32.4)
 41–50 128 (10.7)
 ≥51 58 (4.8)
Sex (n = 1196)
 Female 666 (55.7)
 Male 530 (44.3)
Baseline functional status (n = 1047)
 Working 651 (62.2)
 Ambulatory 345 (33.0)
 Bedridden 51 (4.8)
Baseline WHO clinical stage (1196)
 Stage 1 61 (5.1)
 Stage 2 180 (15.0)
 Stage 3 809 (67.7)
 Stage 4 146 (12.2)
First treatment class (n = 1196)
 AZT-3TC 732 (61.2)
 D4t-3TC 36 (3.0)





Baseline CD4 count (n = 1196)
 <200 919 (76.8)
 200–349 218 (18.2)
 350–499 32 (2.7)
 ≥500 27 (2.3)
Average CD4 count increment (compared to the baseline)a
 At 6 month (n = 861) 228 (60.26)
 At 1 year (n = 787) 232 (60.66)
 At 2 year (n = 701) 229 (60.33)
 At 3 year (n = 569) 264 (63.73)
 At 4 year (n = 378) 303 (66.87)
Fig. 1 Trend of CD4 count by sex of ART attendants, Felege Hiwot 
Referral Hospital, 2010–2014
Fig. 2 Individual trajectories of the CD4 count of the first 30 ART 
attendants over time, Felege Hiwot Referral Hospital, 2010–2014
Table 2 Variability of  intercepts of  the null model, Felege 
Hiwot Referral Hospital, 2010–2014
Parameter Estimate p value
Residual 21041.196 <0.01
Variance for intercepts 44296.370 <0.001
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WHO clinical stage, sex (all from level-2), and average 
distance between residence and the hospital (from level-
3) were considered to see their effect on CD4 count. In 
line with this, an intercept only random effect was used 
at the first block to account for the correlation between 
individuals in the same district or locality. Random inter-
cept and linear effects were also requested at the second 
block to account for the correlation between repeated 
CD4 counts of each patient.
Therefore, in addition to the fixed intercept, the fixed 
effects of baseline CD4 count, initial age, baseline func-
tional status, and time were estimated to be statistically 
significant. The fixed effect of the interaction between 
baseline functional status and time was also significant. 
However, sex, baseline WHO clinical stage, distance 
from patient’s residence to the hospital, and the inter-
action of other categorical variables with time were 
not found to be independent predictors of CD4 count. 
Before presenting the results of this third model, the sig-
nificance of its fit was compared with the two models 
considered so far to facilitate the process of model selec-
tion (Table 3).
Accordingly, because the third model containing 
other fixed predictors had the smallest BIC value, it was 
selected as the best fit for the data. For instance, when 
the null model was compared with the third one, there 
was a statistically significant difference in fit because the 
change in BIC = 719.08, and this was significant at Chi 
square with 9 df (degrees of freedom). The residual error 
variance also dropped from 21041.20 to 18600.83, imply-
ing that about 11.6  % of the within individual variation 
in CD4 count was associated with the linear effect of 
independent variables considered. In line with determin-
ing the fixed effects, the random effects were also deter-
mined by comparing different covariance structures. In 
this regard, the unstructured covariance structure gave 
the least information criterion and was selected to model 
the random effect.
Therefore, it was found that keeping all other vari-
ables constant, for a unit increase in the baseline CD4 
count, the CD4 count of a participant would increase 
by 0.820  cells/mm3. For each additional half year, the 
CD4 count of ambulatory or bedridden patients would 
increase on average by 8.69 cells/mm3 (1.45  cells/mm3 
per month or 17.38 cells/mm3 per year) (p value <0.001). 
However, for working status patients, the mean CD4 
count increment for each subsequent half year was 6.59 
cells/mm3 more when compared to ambulatory or bed-
ridden patients’ or a total gain of 15.28 (8.69  +  6.59) 
cells/mm3 which was equivalent to 2.55 cells/mm3 per 
month or 30.56 cells/mm3 per year. The model intercepts 
of ambulatory/bedridden and working status patients 
were 377.6 and 358.5 (377.6−19.1), respectively. For each 
additional 1  year of baseline age, the CD4 count would 
decrease by 5.0 cells/mm3. However, females’ CD4 count 
was not found to be statistically significantly different 
from that of males (Table 4).
The covariance structure
The adequacy of the model fitted could also be affected 
by the error covariance structure selected. This is because 
the distribution of errors requires which error covariance 
structure should be employed. As a result, three differ-
ent variance- covariance structures were compared for 
each candidate model. Because the unstructured matrix 
gave the least information criterion in all possible com-
binations, it was selected to determine the random effect 
(Table 5).
However, the variance of intercepts at block 1 (a block 
that measures the variability of parameters from differ-
ent districts within which individuals were clustered) 
was not found to be significantly different from zero 
(Variance = 3167.58, p value = 0.123). Conversely, both 
Table 3 The fit and residual values of three models, Felege 
Hiwot Referral Hospital, 2010–2014
BIC bayesian information criteria
Model BIC Residual error
The null model 67978.414 21041.20
Unconditional linear model 67790.95 18744.68
A model included other predictors 67259.324 18600.83
Table 4 Fixed effects on CD4 count, Felege Hiwot Referral 
Hospital, Ethiopia, 2010–2014
Characteristics Coefficient 95 % CI p value
Lower Upper
Intercept 377.6 359.38 455.58 <0.001
Baseline CD4 0.818 0.73 0.91 <0.001
Baseline age −5.0 −6.0 −3.95 <0.001
Sex of a patient
 Female 17.11 −5.52 39.74 0.238
 Male 0.0
Baseline WHO clinical stage
 WHO stage 1 and 2 −15.33 −48.01 17.35 0.358
 WHO stage 3 and 4 0.0
Time in treatment 8.69 4.34 13.03 <0.001
Functional status (baseline)
 Working −19.1 −29.1 −9.1 <0.001
 Ambulatory/bedridden 0.0
Functional status × time in treatment
 Working × time in treatment 6.59 1.49 11.68 0.011
 Ambulatory/bedrid-
den × time in treatment 
0.0
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random intercept and random slope at block 2 (a block 
that measures the variability of parameters of repeated 
data clustered within individuals) were significantly dif-
ferent from zero (Table  6). Specifically, the variance of 
the random deviations about the fixed intercept and fixed 
slope of time were 25686.53 and 382.80, respectively, 
each with a p value of less than 0.001.
Discussion
In this multi-level analysis to measure the effect of differ-
ent covariates on the CD4 count over time, the random 
effect from the third level was not significant (Table  3). 
This can also be confirmed by the variability of random 
intercepts (3167.58) which was much less than the resid-
ual variability (18600.83). Therefore, the contribution of 
the variability of CD4 count among individuals clustered 
by districts at the third level was not found to be statisti-
cally significant (block 1).
Similarly, the effect of a fixed variable from the third 
level which was the average distance of patients’ resi-
dence from the hospital was not found to be an inde-
pendent predictor of CD4 count. However, most studies 
done in developing countries [18, 19], including a sys-
tematic review of studies conducted only in sub-Saharan 
Africa [20], reported that distance as one component of 
geographic or transportation-related barriers could end 
up with poor HIV-related outcomes. Long travel time 
to the clinic could also force individuals to come late to 
the service center [21] which could again result in poor 
health outcome as the immune system could already be 
damaged [13].
On the contrary, few studies reported favorable impacts 
of geographic and transportation-related barriers on HIV 
outcomes [22, 23] among which distance was one of the 
barriers. As a justification to this paradoxical finding, it 
was reported that for patients who lost to follow up from 
a clinic, greater distance to the service center was asso-
ciated with increased likelihood of re-establishing care 
at different sites; this was because different clinics were 
established with the aim of decentralizing the service 
[22], and this situation could have improved their adher-
ence and then their health outcome [24, 25]. Partly it 
could also be due to fear of stigma that could force HIV 
patients to go to distant service centers for their anonym-
ity, which is a common practice in most African settings 
[26]. Such persons who are highly motivated and inten-
tionally prefer distant health care facilities to minimize 
stigma could have better HIV treatment adherence [27] 
that could change the usual association between distance 
and HIV- related health outcomes into a paradoxical one.
Therefore, if there are possibilities for both positive 
and negative associations between distance and HIV- 
treatment outcomes, it is also possible to get a null find-
ing just similar to that of the current study. This is partly 
because the factors that could give positive and negative 
outcomes could nullify each other when present almost 
equivalently in the population under investigation. 
Other studies, for instance, a study done in Uganda [28] 
obtained a null finding because the design used excluded 
participants living more than 20  km from the clinic. 
Exclusion of participants from long distance could leave 
the population under investigation nearly homogeneous, 
regarding distance from the service center.
The other possible reason for the null result in the cur-
rent study is that even though some individuals’ localities 
could be closer to the hospital when measured in kilo-
meters, they might not be accessible as there are some 
rural villages that do not have transportation facilities 
and could require 4–6 h walk. However, as can be seen 
from the data, participants who lived in towns 200  km 
from the service center, for example, could easily access 
the services because of the availability of transportation 
infrastructure which could improve their adherence level 
and probably their treatment outcome [25]. The existence 
of such contradictory evidence about ART users who live 
close to and far from services centers could lead to inde-
terminable results.
However, in the second (individual) level, some of the 
reasons for the variability of CD4 counts were deter-
mined to be baseline CD4 count, baseline age, time since 
the initiation of ART, baseline functional status, and its 
interaction with time. Baseline CD4 count was positively 
Table 5 Comparing covariance structures for  a model 
with  fixed predictors and  random effects, Felege Hiwot 
Referral Hospital, 2010–2014
−2LL log likelihood, AIC akakie information criteria, BIC Bayesian information 
criteria
Covariance structure −2LL AIC BIC
Unstructured 67225.147 67233.155 67259.324
Compound symmetry 67757.63 67763.636 67788.451
AR (1) 67758.375 67767.636 67803.264
Table 6 Random effects of intercepts and slopes at block 2 
for the a model with fixed predictors, Felege Hiwot Refer-
ral Hospital, 2010–2014
UN unstructured covariance
Random effect Estimate 95 % CI for the estimate p value
Lower Upper
UN (1, 1) 25686.53 22065.43 29901.87 <0.001
UN (1, 2) −1059.39 −1641.44 −477.33 <0.001
UN (2, 2) 382.80 275.87 531.18 <0.001
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associated with CD4 count during treatment; for each 
subsequent baseline CD4 count, the average gain in CD4 
count during the treatment is about 0.818  cells/mm3. 
Some studies also reported positive associations between 
these characteristics [14]. Other studies reported con-
flicting evidence claiming a negative association between 
baseline CD4 count and CD4 count during the treatment 
period [6, 8]. In fact, the nature of the parameters esti-
mated in these contradicting studies is different. The cur-
rent study measured just the average gain in CD4 count 
for each additional baseline CD4 count; but the studies 
which reported negative associations estimated the aver-
age rate of increment or slope per unit time which could 
diminish over time until it reaches a plateau.
Baseline age was negatively associated with CD4 count 
response which was supported by other studies [6, 29]. 
Different authors reasoned out that a favorable influ-
ence of younger age on CD4 cell recovery while a patient 
is receiving HAART may be explained by more-effective 
thymic function [29]. It was also shown that older per-
sons come to the clinic late [21], and that could place 
them into poor response to ART treatment [13]. On 
the contrary, other studies reported a null association 
between age and CD4 count increment [8, 30]. This could 
probably be because the majority of the patients were less 
than 50 years old [8], and 50 % of the participants were 
between 31 and 41 years old [30] in the respective stud-
ies, and in both cases the relative homogeneity in age 
could dilute its effect on CD4 count increment.
When adjusted for other variables, sex was not found 
to be an independent predictor of CD4 count which was 
in agreement with other findings [5, 8]. In contrast, other 
authors reported that females had better response to 
ART as compared to males [7]. One common justification 
is that females could attend voluntary counseling and 
testing as part of their routine health care services during 
pregnancy, while male patients are poor in their health 
seeking behavior as they experience lower rates of HIV 
testing, repeated-testing, and acceptance of linkage to 
HIV-care after a positive result [31]. As a result, females 
are more likely to be diagnosed for infection earlier than 
males [21, 32], and this could make the response to ART 
treatment poor for late diagnosed males as the immune 
system could be damaged irreversibly in advanced stages 
of the disease [13]. However, early presentation and 
health seeking behavior might have been indifferent for 
males and females in the present study population giving 
a statistically insignificant result.
The two levels of patients’ baseline functional status 
were found to be statistically significantly different both 
in their initial status (intercept) and linear change (slope) 
of their CD4 count. Another study done in eastern 
Ethiopia also reported a significant association between 
functional status and change of CD4 count [33]. Oppor-
tunistic infections at the start of ART [30] and during the 
treatment period could affect the CD4 count change over 
time. Thus, patients who were at a ‘working’ status could 
be in a better position with regard to co-infection and 
similar reasons that could influence the response to ART 
than their counter parts (‘ambulatory/bedridden’).
Time since the initiation of ART was also an independ-
ent predictor of CD4 count. Other authors also reported 
that from 3  months onward, a greater cumulative pro-
portion of time spent with a virus load <400 copies/mL 
was associated with a more favorable change in CD4 
cell count [8]. In the present study, for patients who had 
‘working’ functional status, the mean CD4 count would 
increase by 30.56  cells/mm3 per year (p value =  0.011). 
The corresponding value for ‘ambulatory/bedridden’ 
patients was even smaller (17.38  cells/mm3 per year). 
These values were smaller than the finding of another 
study that reported 38.74  %  cells/mm3 [5]. It was also 
much less than a study that estimated it at 60 % [8].
Similarly, the gain in CD4 count in the present study 
was much less than the recommend value which is 50 to 
100 cells/mm3 per year so that a patient should respond 
to treatment after 3 months of initiation of ART until a 
steady state level is reached [4]. Of course, there is some 
difficulty of comparing it directly with the recommended 
value because the present study modeled data obtained 
6 months after the initiation of the treatment, while the 
standard is set for data obtained after 3  months of ini-
tiation, and the 3  month difference could have brought 
some difference in the estimated slope [4] as the CD4 
count in earlier times is usually high. However, because 
the observed increment rates were so small compared to 
the recommended value, it is very difficult to expect the 
increment to be in the recommended range for similar 
period of CD4 count data measurement.
In the current study, the 378 participants who contin-
ued until the end of year 4 getting the treatment in the 
hospital had a mean (+SD) CD4 count of 453 (+222) 
cells/mm3 at year 4, which was much less than the CD4 
count of healthy HIV negative Ethiopians, reported as 
747 (+333) by a study done on Akaki factory workers 
[34] and 820 (+270) by a study done at the University of 
Gondar Hospital [35]. This signifies that patients were 
less likely to reach the local normal range of CD4 count 
after 4 years of treatment. Moreover, only 37.6 % of them 
reached a CD4 count of 500 or more cells/mm3, while 
the corresponding values reported by other authors were 
45.2  % [30] and 59  % [36]. Of course, partly this could 
probably be because Ethiopians might have a relatively 
lower normal CD4 count, compared to most other study 
populations. For instance, it was lower than that of the 
Dutch [34], Ugandans [37], and Tanzanians [38]; and if 
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the normal CD4 count is relatively low, the magnitude of 
increment could also be comparatively smaller. However, 
as the observed differences are considerably large and 
all the evidences mentioned are multi-faced, the poor 
response to ART could be a real problem.
Finally, in this second (individual) level, the variability 
of initials (intercepts) of the CD4 count due to individual 
trajectories and the corresponding rates of increment 
(slopes) were found to be statistically significant (each 
with p value <0.001). Moreover, the variability between 
the intercepts (25686.53) was greater than the within var-
iability (18600.83). This indicates that the other reasons 
for CD4 count variability which was not explained by the 
fixed variables considered (base line age, baseline CD4 
count, time in treatment, and functional status) were rep-
resented by the random effects of intercept and slope at 
individual levels (block 2). This is also the variability cap-
tured by the random effect due to uncontrolled (unmeas-
ured) variables.
Limitations
There are some limitations that should be considered in 
this paper. Firstly, because the study was based on record 
review and data was not available for some relevant vari-
ables (e.g. patients’ nutritional status), the effect of such 
unmeasured variables were not estimated separately. 
However, because a random effect model was used, the 
contribution of all unmeasured variables was pooled out 
from the total variability to get the adjusted effect of the 
independent variables considered. Secondly, data should 
have been available at least on the 3rd month after the 
initiation of ART where the increment of CD4 count was 
high so that the trend will be observed in detail and be 
comparable with more other studies and standards set for 
better management.
Conclusion
In this study, higher baseline CD4 count, younger age, 
working functional status, and time in treatment con-
tributed positively to the increment of CD4 count. How-
ever, the observed increment at 4 year was unsatisfactory 
as the proportion of ART users who reached the normal 
range of CD4 count (for the general healthy adult popula-
tion) was very low. To see their long term treatment out-
come, it requires further research with sufficiently longer 
follow up data. In line with this, the local normal CD4 
count should also be investigated for better comparison 
and proper disease management.
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